



Neuland Laboratories Limited
11th Floor (5th Office Level),
Phoenix IVY Building,
Plot No.573A-III, Road No.82,
Jubilee Hills, Hyderabad - 500033,
Telangana, India.

Tel: 040 67611600 / 67611700
Email: neuland@neulandlabs.com
www.neulandlabs.com

May 11, 2023

To
BSE Limited
Phiroze Jeejeebhoy Towers, 25th Floor, Dalal
Street, Mumbai - 400 001

The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB; Series: EQ

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors of the Company at its meeting held on May 11, 2023, has *inter alia* approved the following:

1. Re-appointment of Mr. Davuluri Sucheth Rao (DIN: 00108880) as Whole Time Director of the Company designated as Vice Chairman & CEO, for a further period of 5 (five) years, w.e.f. August 1, 2023, basis the recommendation of the Nomination and Remuneration Committee, subject to the approval of the shareholders of the Company in the ensuing Annual General Meeting.
2. Re-appointment of Dr. Davuluri Rama Mohan Rao (DIN: 00107737) as Whole Time Director of the Company designated as Executive Chairman, for a further period of 5 (five) years, w.e.f. April 1, 2024, basis the recommendation of the Nomination and Remuneration Committee, subject to the approval of the shareholders of the Company in the ensuing Annual General Meeting.

The details as required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, with respect to the above re-appointments are enclosed as **Annexure A**.

3. Convening the 39th Annual General Meeting (AGM) of the members of the Company on Thursday, July 27, 2023.

The Register of Members and the Share Transfer Books of the Company shall remain closed from Wednesday, July 12, 2023, to Friday, July 14, 2023 (both days inclusive) for the purpose of the Dividend and Annual General Meeting of the Company.

This is for your information and records.

Thanking you,

Yours Sincerely,
For **Neuland Laboratories Limited**

Sarada Bhamidipati
Company Secretary

Encl: As above

Annexure A

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015

Details of Mr. Davuluri Sucheth Rao

| Sl. No. | Particulars | Remarks |
|---------|---|--|
| 1. | DIN | 00108880 |
| 2. | Reason for change viz. appointment, resignation, removal, death or otherwise | Re-appointment |
| 3. | Date of appointment and term of appointment | Re-appointment as Whole Time Director of the Company designated as Vice Chairman & CEO, for a further period of 5 (five) years, w.e.f. August 1, 2023, subject to the approval of the shareholders of the Company in the ensuing Annual General Meeting. |
| 4. | Brief Profile | Mr. D. Sucheth Rao, Vice-Chairman and Chief Executive Officer, has a degree in Mechanical Engineering and holds an MBA in Corporate Finance and Operations Management from University of Notre Dame, U.S.A. He was Production Group Leader in Cummins Inc., U.S.A. and later went on to become a green belt in Six Sigma. He has been actively involved in managing Neuland since 2002, initially as Chief Operating Officer (COO) and then as CEO and has been instrumental in the growth of the Company. |
| 5. | Disclosure of relationships between directors | Mr. D. Sucheth Rao is son of Dr. D. Rama Mohan Rao, Executive Chairman, and brother of Mr. D. Saharsh Rao, Vice Chairman and Managing Director, of the Company. |
| 6. | Information as required pursuant to BSE Circular with ref. no. LIST/ COMP/ 14/ 2018-19 and the National Stock Exchange of India Ltd with ref. no. NSE/ CML/ 2018/24, dated 20th June 2018 | Mr. Davuluri Sucheth Rao is not debarred from holding the office of director by virtue of any SEBI order or any other such authority. |

Details of Dr. Davuluri Rama Mohan Rao

| Sl. No. | Particulars | Remarks |
|---------|---|--|
| 1. | DIN | 00107737 |
| 2. | Reason for change viz. appointment, resignation, removal, death or otherwise | Re-appointment |
| 3. | Date of appointment and term of appointment | Re-appointment as Whole Time Director of the Company, designated as Executive Chairman, for a further period of 5 (five) years, w.e.f. April 1, 2024, subject to the approval of the shareholders of the Company in the ensuing Annual General Meeting. |
| 4. | Brief Profile | Dr. D. Rama Mohan Rao, Executive Chairman, is the Chief Promoter of Neuland. He has a Masters in Science from Andhra University, Post Graduate Diploma in Technology from IIT Kharagpur and a PhD in Organic Chemistry from the University of Notre Dame, U.S.A. Prior to founding Neuland in 1984, he had held senior positions in R&D, production and quality assurance at Glaxo India for about ten years and was Director, R&D and QA at another Pharmaceutical company. He is a member of the Royal Society of Chemistry. |
| 5. | Disclosure of relationships between directors | Mr. D. Sucheth Rao, Vice Chairman & CEO, and Mr. D. Saharsh Rao, Vice Chairman & Managing Director, of the Company are the sons of Dr. D. Rama Mohan Rao. |
| 6. | Information as required pursuant to BSE Circular with ref. no. LIST/ COMP/ 14/ 2018-19 and the National Stock Exchange of India Ltd with ref. no. NSE/ CML/ 2018/24, dated 20th June 2018 | Dr. D. Rama Mohan Rao is not debarred from holding the office of director by virtue of any SEBI order or any other such authority. |